REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
In this series a panel of seven academics, journalists and historians named her among the group of people in the UK "whose actions during the reign of Elizabeth II have had a significant impact on lives in these islands and given the age its character". In 2015 Hodgkin's 1949 paper The X-ray Crystallographic Investigation of the Structure of Penicillin was honoured by a Citation for Chemical Breakthrough Award from the Division of History of Chemistry of the American Chemical Society presented to the University of Oxford (England). This research is notable for its groundbreaking use of X-ray crystallography to determine the structure of complex natural products, in this instance, of penicillin. Since 1999, the Oxford International Women's Festival has presented the annual Dorothy Hodgkin Memorial Lecture, usually in March, in honour of Hodgkin's work. The Lecture is a collaboration between Oxford AWiSE (Association for Women in Science & Engineering), Somerville College and the Oxford University Museum of Natural History.
=== Order of battle, 1939 === Headquarters (Columbia, SC) Headquarters, Special Troops (Columbia, SC) Headquarters Company (Columbia, SC) 163rd Infantry Brigade (Atlanta, GA) 325th Infantry Regiment (Albany, GA) 326th Infantry Regiment (Atlanta, GA) 164th Infantry Brigade (Tampa, FL) 327th Infantry Regiment (Greenville, SC) 328th Infantry Regiment (Tampa, FL) 157th Field Artillery Brigade (Spartanburg, SC) 319th Field Artillery Regiment (Decatur, GA) 320th Field Artillery Regiment (Spartanburg, SC) 321st Field Artillery Regiment (Macon, GA) 307th Ammunition Train (Newberry, SC) 307th Engineer Regiment (Jacksonville, FL) 307th Medical Regiment (Macon, GA) 407th Quartermaster Regiment (Augusta, GA) 82nd Military Police Company (Columbia, SC) 82nd Signal Company (Macon, GA) 307th Ordnance Company (Medium) (Savannah, GA) 82nd Tank Company (Light) (Columbus, GA)
There are over 800 extant species of cephalopod, although new species continue to be described. An estimated 11,000 extinct taxa have been described, although the soft-bodied nature of cephalopods means they are not easily fossilised. Cephalopods are found in all the oceans of Earth. None of them can tolerate fresh water, but the brief squid, Lolliguncula brevis, found in the Chesapeake Bay, is a notable partial exception in that it tolerates brackish water. Cephalopods are thought to be unable to live in fresh water due to multiple biochemical constraints, and in their >400 million year existence have never ventured into fully freshwater habitats. Cephalopods occupy most of the depth of the ocean, from the abyssal plains to the sea surface, and have also been found in the hadal zone. Their diversity is greatest near the equator (~40 species retrieved in nets at 11°N by a diversity study) and decreases towards the poles (~5 species captured at 60°N).
Symptomatic coeliac disease (characterised by symptoms related to gluten) can be further categorised into classical and non-classical. Classical coeliac disease, which in the past has also been called typical coeliac disease, is coeliac disease presenting with malnutrition, malabsorption, and diarrhoea. Non-classical coeliac disease, historically referred to as atypical coeliac disease, is when individuals primarily present with symptoms unrelated to malabsorption. Potential coeliac disease refers to those who have positive serology for coeliac disease but no changes in the small intestine. The term latent coeliac disease has been used interchangeably with potential coeliac disease, but has no consistent definition, and its use is therefore discouraged. Sometimes, those with coeliac disease will continue to experience symptoms or signs of the disease despite being on a gluten-free diet. "Slow responders" or "non responsive coeliac disease" (NRCD) is the persistence of symptoms despite exclusion of gluten for 6 to 12 months. Refractory coeliac disease (RCD) is the persistence of malabsorption and damage to the small intestine after at least 12 months of a gluten-free diet. Most people with NRCD do not have RCD; instead, their symptoms are caused by some other factor. There are two types of RCD: type one has histopathological changes similar to those seen in untreated coeliac disease, whereas type two has abnormal histopathological changes not consistent with untreated coeliac disease.
In statistical copolymers the sequence of monomer residues follows a statistical rule. If the probability of finding a given type monomer residue at a particular point in the chain is equal to the mole fraction of that monomer residue in the chain, then the polymer may be referred to as a truly random copolymer (structure 3). Statistical copolymers are dictated by the reaction kinetics of the two chemically distinct monomer reactants, and are commonly referred to interchangeably as "random" in the polymer literature. As with other types of copolymers, random copolymers can have interesting and commercially desirable properties that blend those of the individual homopolymers. Examples of commercially relevant random copolymers include rubbers made from styrene-butadiene copolymers and resins from styrene-acrylic or methacrylic acid derivatives. Copolymerization is particularly useful in tuning the glass transition temperature, which is important in the operating conditions of polymers; it is assumed that each monomer occupies the same amount of free volume whether it is in a copolymer or homopolymer, so the glass transition temperature (Tg) falls between the values for each homopolymer and is dictated by the mole or mass fraction of each component. A number of parameters are relevant in the composition of the polymer product; namely, one must consider the reactivity ratio of each component. Reactivity ratios describe whether the monomer reacts preferentially with a segment of the same type or of the other type.
Sources: en.wikipedia.org
== Further reading == Bishop, Michael; Duben-Engelkirk, Janet L., and Fody, Edward P. (1992). "Chapter 19, Liver Function, Clinical Chemistry Principles, Procedures, Correlations, 2nd Ed." Philadelphia, J.B. Lippincott Company. Miyabara, Yuichi; Tabata, Masako; Suzuki, Junzo; Suzuki, Shizuo (1992). "Separation and sensitive determination of i-urobilin and 1-stercobilin by high-performance liquid chromatography with fluorimetric detection". Journal of Chromatography B: Biomedical Sciences and Applications. 574 (2): 261–265. doi:10.1016/0378-4347(92)80038-R. PMID 1618958. Miyabara, Y.; Sakata, Y.; Suzuki, J.; Suzuki, S. (1994). "Estimation of faecal pollution based on the amounts of urobilins in urban rivers". Environmental Pollution. 84 (2): 117–122. doi:10.1016/0269-7491(94)90093-0. PMID 15091706. Munson-Ringsrud, Karen and Jorgenson-Linné, Jean (1995). "Urinalysis and Body Fluids, a ColorText and Atlas." St. Louis, Mosby. Nelson, L.; David, Cox M.M. (2005). “Chapter 22 – Biosynthesis of Amino Acids, Nucleotides, and Related Molecules”, pp. 856, In Lehninger Principles of Biochemistry. Freeman, New York. pp. 856. Voet, Donald; Voet, Judith G.; Pratt, Charlotte W. (2018-01-23). Voet's Principles of Biochemistry, Global Edition, 5th Edition. Wiley. p. 1200. ISBN 978-1-119-45166-2. Retrieved 2024-02-01.
deacetylation The removal of an acetyl group (–COCH3) from a chemical compound, protein, or other biomolecule via hydrolysis of the covalent ester bond adhering it, either spontaneously or by enzymatic catalysis. Deacetylation is the opposite of acetylation.
Genome analysis reveal rifampicin resistant strains have a mutation in rpoA and rpoC. A similar study investigated the bacterial fitness associated with compensatory mutations in rifampin resistant Escherichia coli. Results obtained from this study demonstrate that drug resistance is linked to bacterial fitness as higher fitness costs are linked to greater transcription errors.
==== Advantage of argon ==== Making the plasma from argon, instead of other gases, has several advantages. First, argon is abundant (in the atmosphere, as a result of the radioactive decay of potassium) and therefore cheaper than other noble gases. Argon also has a higher first ionization potential than all other elements except He, F, and Ne. Because of this high ionization energy, the reaction (Ar+ + e− → Ar) is more energetically favorable than the reaction (M+ + e− → M). This ensures that the sample remains ionized (as M+) so that the mass spectrometer can detect it. Argon can be purchased for use with the ICP-MS in either a refrigerated liquid or a gas form. It should have a guaranteed purity of 99.9% Argon at a minimum. It is important to determine which type of argon will be best suited for the specific situation. Liquid argon is typically cheaper and can be stored in a greater quantity as opposed to the gas form, which is more expensive and takes up more tank space. If the instrument is in an environment where it gets infrequent use, then buying argon in the gas state will be most appropriate as it will be more than enough to suit smaller run times and gas in the cylinder will remain stable for longer periods of time, whereas liquid argon will suffer loss to the environment due to venting of the tank when stored over extended time frames. However, if the ICP-MS is to be used routinely and is on and running for eight or more hours each day for several days a week, then going with liquid argon will be the most suitable.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.